Lantheus’ (LNTH) Hold Rating Reiterated at Truist Financial

Truist Financial reaffirmed their hold rating on shares of Lantheus (NASDAQ:LNTH) in a research note released on Monday morning,Benzinga reports. The brokerage currently has a $61.00 price target on the medical equipment provider’s stock, down from their previous price target of $63.00.

A number of other research analysts have also commented on LNTH. Weiss Ratings lowered shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. B. Riley lowered their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research report on Tuesday, September 16th. TD Cowen cut their price objective on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, September 15th. JMP Securities lowered their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a report on Thursday, August 7th. Finally, Mizuho dropped their price target on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Lantheus presently has an average rating of “Hold” and an average price target of $74.17.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $54.50 on Monday. The stock has a market cap of $3.61 billion, a P/E ratio of 14.49 and a beta of 0.04. The firm’s 50-day simple moving average is $53.95 and its 200 day simple moving average is $67.46. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $111.29. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The firm had revenue of $92.51 million during the quarter. Equities analysts expect that Lantheus will post 6.01 EPS for the current year.

Insiders Place Their Bets

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of the business’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 6,812,000 shares of company stock worth $382,427,380 over the last ninety days. 2.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Lantheus

Large investors have recently made changes to their positions in the company. Heron Bay Capital Management purchased a new stake in shares of Lantheus in the 3rd quarter valued at approximately $861,000. Victory Capital Management Inc. raised its stake in Lantheus by 3.4% during the 3rd quarter. Victory Capital Management Inc. now owns 140,335 shares of the medical equipment provider’s stock valued at $7,198,000 after purchasing an additional 4,587 shares during the period. 111 Capital purchased a new stake in shares of Lantheus in the third quarter valued at $201,000. Elo Mutual Pension Insurance Co acquired a new stake in shares of Lantheus in the third quarter worth $942,000. Finally, William Blair Investment Management LLC grew its holdings in shares of Lantheus by 46.7% during the third quarter. William Blair Investment Management LLC now owns 574,681 shares of the medical equipment provider’s stock valued at $29,475,000 after buying an additional 183,059 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.